Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stability At Last For Drug Innovators And Pricing In Australia

Executive Summary

The Australian government has promised not to implement any new therapeutic groups under the Pharmaceutical Benefits Scheme for the next five years, nor will it introduce any new pricing reforms without consulting the innovative drug industry first.

You may also be interested in...

Australian Drug Industry Lays Out Wishlist As Elections Near

With the government and opposition parties in Australia in full pre-election promise mode, the pharmaceutical industry has called on the future government to guarantee the sustainability of the drug reimbursement system, extend the data exclusivity period and review the National Medicines Policy on access to new drugs.

Australian Bill Brings Further Price Cuts But Promise Of More New Drug Listings

A new bill just approved in Australia will introduce further price cuts in order to reap savings on the pharmaceutical bill, which will partly be used to fund the reimbursement listing of new drugs. The pharmaceutical industry will also benefit from a more predictable pricing environment, at least until 2022. 

Australian Firms Face Higher PBS Fees As Govt Seeks To Cover Assessment Costs

Australian pharmaceutical companies are facing possible increases in the fees they have to pay for applications to have medicines listed on the Pharmaceutical Benefits Scheme, as the government proceeds with plans to ensure fee revenues cover the full cost of assessment work.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts